• Japan Lifeline agreed to buy Cross Vascular, via wholly owned subsidiary JLL Med USA, making it an indirect wholly owned unit.
• Deal values Cross Vascular common shares at USD 4,734,000, including USD 734,000 at closing and up to USD 4,000,000 earn-out.
• Advisory fees and related costs estimated at JPY 234 million, taking total estimated outlay to about JPY 977 million.
• Signing and closing are scheduled for Sept. 30, 2026.
• JLL Med USA will inject USD 7,265,000 into Cross Vascular, lifting capital to USD 7,274,000 for debt payments, working capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JLL - Japan Lifeline Co. Ltd. published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein.